Avedro (Waltham, MA) landed a CE Mark in the European Union for its non-surgical myopia treatment device. The device, dubbed KXL II, can perform a photorefractive intrastromal cross-linking procedure, allowing for the correction of myopia. In addition, the device can be used to improve outcomes for cataract surgery.
In March, Avedro raised $43 million in a funding round. That round was led by Abingworth and Third Point.
"The KXL II and PiXL procedure continue our mission to make refractive correction truly non-surgical. Treating myopia and other refractive disorders with PiXL has the potential to open up refractive correction to millions of people who have never considered Lasik surgery before, but would consider a non-surgical alternative," stated CEO David Muller.
Avedro is a privately-held company that manufactures a variety of pharmaceuticals and medical devices. The KXL and some of the company’s pharmaceuticals are currently being used in Phase III clinical trials in the United States.
